Zoraxel Phase II trial is a double-blind, placebo-controlled study. This multi-center trial is expected to be completed by the end of 2008. Zoraxel is being developed as an orally administered, on-demand-use tablet.
Chang Ahn, chairman and CEO of Rexahn, said: “We are very pleased to announce the initiation of another Phase II trial. Zoraxel will prove itself a more effective, less toxic therapy for patients with erectile dysfunction.”